United Therapeutics’ Once-Daily Pill Cuts Clinical Worsening in PAH by 55%

United Therapeutics' ralinepag reduced clinical worsening risk by 55% in PAH phase 3 study. Once-daily oral drug shows strong efficacy; FDA filing planned for 2026.